(2S,3S,4R)-1-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyloxy)-2-(tetracosanoylamino)nonane-3,4-diol | 745042-02-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2S,3S,4R)-1-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyloxy)-2-(tetracosanoylamino)nonane-3,4-diol
• 英文别名: (2S,3S,4R)-2-(tetracosanoylamino)-1-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)nonan-3,4-diol；2-tetracosanoylamino-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-D-ribo-1,3,4-nonanetriol；N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5S,6R)-3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-yl]oxynonan-2-yl]tetracosanamide
• CAS: 745042-02-8
• 化学式: C₆₇H₁₀₁NO₉
• 分子量: 1064.54
• InChiKey: JAHZOKOULCXNRD-VGEKJMBPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  17.7
• 重原子数：
  77
• 可旋转键数：
  45
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  125
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  (2S,3S,4R)-1-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyloxy)-2-(tetracosanoylamino)nonane-3,4-diol 在 palladium dihydroxide 氢气 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 3.0h， 以100%的产率得到(2S,3S,4R)-1-O-(α-D-galactopyranosyl)-2-(N-tetracosanoylamino)-1,3,4-nonanetriol
  参考文献：
  名称：

  免疫抑制性糖脂（2S，3S，4R）-1 - O-（α-d-半乳糖基）-2-四cosanoylamino-1,3,4-壬三醇的全合成

  摘要：

  实用有效的全合成（2S，3S，4R）-1- O-（α - d-半乳糖基）-2-四cosanoylamino-1,3,4-壬三醇OCH 1b（Th1介导的潜在治疗候选物）描述了自身免疫性疾病。该合成将直接烷基化结合到环氧化物5上，并通过立体特异性卤化物离子催化的α-糖基化反应。从市售的d-阿拉伯糖醇2和1b的总合成中，仅需八步即可获得关键中间体10，总收率达到37％。分12步完成，总收率19％。该方法将能够以高度立体选择性的方式合成多种植物鞘氨醇脂，特别是具有比1a短的鞘氨醇侧链的植物鞘氨醇脂。

  DOI：

  10.1021/jo048151y
• 作为产物：
  描述：

  D-Arabitol 在 palladium dihydroxide 、 Lindlar's catalyst 吡啶 、 盐酸 、 copper(l) iodide 、 sodium azide 、 三氟化硼乙醚 、 potassium tert-butylate 、 氢气 、 二正丁基氧化锡 、 1-羟基苯并三唑 、 对甲苯磺酸 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 、 正己烷 、 二氯甲烷 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 172.0h， 生成 (2S,3S,4R)-1-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyloxy)-2-(tetracosanoylamino)nonane-3,4-diol
  参考文献：
  名称：

  免疫抑制性糖脂（2S，3S，4R）-1 - O-（α-d-半乳糖基）-2-四cosanoylamino-1,3,4-壬三醇的全合成

  摘要：

  实用有效的全合成（2S，3S，4R）-1- O-（α - d-半乳糖基）-2-四cosanoylamino-1,3,4-壬三醇OCH 1b（Th1介导的潜在治疗候选物）描述了自身免疫性疾病。该合成将直接烷基化结合到环氧化物5上，并通过立体特异性卤化物离子催化的α-糖基化反应。从市售的d-阿拉伯糖醇2和1b的总合成中，仅需八步即可获得关键中间体10，总收率达到37％。分12步完成，总收率19％。该方法将能够以高度立体选择性的方式合成多种植物鞘氨醇脂，特别是具有比1a短的鞘氨醇侧链的植物鞘氨醇脂。

  DOI：

  10.1021/jo048151y

文献信息

• Synthesis and Evaluation of Sphinganine Analogues of KRN7000 and OCH
  作者：Rachel M. Ndonye、Douglas P. Izmirian、Matthew F. Dunn、Karl O. A. Yu、Steven A. Porcelli、Archana Khurana、Mitchell Kronenberg、Stewart K. Richardson、Amy R. Howell

  DOI：10.1021/jo051147h

  日期：2005.12.1

  The phytosphingosine-containing alpha-galactosylceramides (alpha-GalCers), KRN7000 and OCH, have been shown to activate NKT cells via interaction with CD1d, a member of the CD1 family of antigen presenting proteins. Evidence from KRN7000 stimulation of NKT cells suggests that alpha-GalCers may have applications in the treatment or prevention of a range of viral, bacterial, and autoimmune conditions. Moreover, OCH, a truncated analogue of KRN7000, appears to induce a T(H)2 bias, which could have implications for the treatment of autoimmune and inflammatory conditions. We have prepared the direct sphinganine-containing analogues of KRN7000 and OCH, 1 and 2, and found them to be comparable in activity to the parent compounds in inducing the release of IL-2, IL-4, and IFN gamma. In addition, compound 2 leads to a cytokine bias similar to that seen with OCH. This is significant because sphinganines are more easily accessed than phytosphingosines, which should facilitate SAR studies.
• GLYCOLIPID DERIVATIVES, PROCESS FOR PRODUCTION OF THE SAME, INTERMEDIATES FOR SYNTHESIS THEREOF, AND PROCESS FOR PRODUCTION OF THE INTERMEDIATES
  申请人：Japan as represented by President of National Center of Neurology and Psychiatry Ministry of Health

  公开号：EP1619199B1

  公开（公告）日：2013-12-18
• RCAI-17, 22, 24–26, 29, 31, 34–36, 38–40, and 88, the analogs of KRN7000 with a sulfonamide linkage: Their synthesis and bioactivity for mouse natural killer T cells to produce Th2-biased cytokines
  作者：Takuya Tashiro、Naomi Hongo、Ryusuke Nakagawa、Ken-ichiro Seino、Hiroshi Watarai、Yasuyuki Ishii、Masaru Taniguchi、Kenji Mori

  DOI：10.1016/j.bmc.2008.08.060

  日期：2008.10

  RCAI-17, 22, 24-26, 29, 31, 34-36, 38-40, and 88, the analogs of KRN7000 (1) with a sulfonamide linkage instead of an amide bond, were synthesized to examine their bioactivity for mouse natural killer (NK) T cells. RCAI-17, 22, 24-26, 29, 31, 34-36, and 88 are the aromatic sulfonamide analogs, while RCAI-39 and 40 are the aliphatic ones. RCAI-38 is a C-galactoside analog of RCAI-26, which is the p-toluenesulfonamide analog of KRN7000. According to their bioassay, these sulfonamide analogs were shown to be the stimulants of mouse NKT cells to induce the production of Th2-biased cytokines in vitro, while RCAI-38 did not induce any cytokine production. (C) 2008 Elsevier Ltd. All rights reserved.
• Total Synthesis of an Immunosuppressive Glycolipid, (<i>2S,3S,4R</i>)-1-<i>O</i>- (α-<scp>d</scp>-Galactosyl)-2- tetracosanoylamino-1,3,4-nonanetriol
  作者：Kenji Murata、Tetsuya Toba、Kyoko Nakanishi、Bitoku Takahashi、Takashi Yamamura、Sachiko Miyake、Hirokazu Annoura

  DOI：10.1021/jo048151y

  日期：2005.3.1

  A practical and efficient total synthesis of (2S,3S,4R)-1-O-(α-d-galactosyl)-2-tetracosanoylamino-1,3,4-nonanetriol, OCH 1b, a potential therapeutic candidate for Th1-mediated autoimmune diseases, is described. The synthesis incorporates direct alkylation onto epoxide 5 and stereospecific halide ion catalyzed α-glycosidation reaction. A key intermediate 10 was obtained in only eight steps and 37% overall

  实用有效的全合成（2S，3S，4R）-1- O-（α - d-半乳糖基）-2-四cosanoylamino-1,3,4-壬三醇OCH 1b（Th1介导的潜在治疗候选物）描述了自身免疫性疾病。该合成将直接烷基化结合到环氧化物5上，并通过立体特异性卤化物离子催化的α-糖基化反应。从市售的d-阿拉伯糖醇2和1b的总合成中，仅需八步即可获得关键中间体10，总收率达到37％。分12步完成，总收率19％。该方法将能够以高度立体选择性的方式合成多种植物鞘氨醇脂，特别是具有比1a短的鞘氨醇侧链的植物鞘氨醇脂。